David Scadden - Jul 10, 2025 Form 4 Insider Report for AGIOS PHARMACEUTICALS, INC. (AGIO)

Role
Director
Signature
/s/ William Cook, as Attorney-in-fact for David Scadden
Stock symbol
AGIO
Transactions as of
Jul 10, 2025
Transactions value $
-$30,674
Form type
4
Date filed
7/15/2025, 04:05 PM
Previous filing
Jun 23, 2025
Next filing
Aug 29, 2025

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Scadden David Director C/O AGIOS PHARMACEUTICALS, INC., 88 SIDNEY STREET, CAMBRIDGE /s/ William Cook, as Attorney-in-fact for David Scadden 2025-07-15 0001707715

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AGIO Common stock Options Exercise $25.3K +1.4K +7.95% $18.09 19K Jul 10, 2025 Direct F1
transaction AGIO Common stock Sale -$56K -1.4K -7.37% $40.00 17.6K Jul 10, 2025 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AGIO Stock options (right to buy) Options Exercise $0 -1.4K -4.81% $0.00 27.7K Jul 10, 2025 Common stock 1.4K $18.09 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
F2 This option was granted on June 21, 2022. The shares underlying this option vest 100% one year from grant date.